and ErbB-4 (Olayioye et al., 2000). The EGFR family mental phases enough for model building ( Figure 2B ). The final model was refined to 3.3 Å resolution with an comprises the four members from mammals and one each from Drosophila melanogaster and Caenorhabditis R factor of 25.5% (R free ϭ 32.6%) ( Table 1) as site 1 in domain I and sites 2 and 3 in domain III In the present study, the crystal structure of a 2:2 ( Figure 3A ). In the 2:2 complex, the two EGF ligands are complex of human EGF and EGFR was determined at located 79 Å apart, on the opposite sides of the receptor 3.3 Å . The structure confirms many experimental results dimer. This is consistent with the previous suggestion, reported thus far, such as the residues of EGF involved based on the low probability of fluorescence-resonance in the receptor binding, and further identifies three EGF energy transfer using fluorescent dye-labeled EGF, that binding sites on domains I and III of the receptor. Morethe distance between the two EGF molecules in the over, the dimeric EGF•EGFR structure demonstrates dimeric EGF•EGFR complex was longer than 58 Å (Sako receptor-mediated dimerization, in which the two EGFR et al., 2000). Remarkably, in the center of the 2:2 commolecules are directly bound to each other by interacplex, the two receptor molecules are bound with each tions between each domain II. The same dimerization other through direct interactions between each domain mode was found for an independently determined struc-II. Therefore, the mechanism of the EGFR dimerization ture of the 2:2 complex of TGF-␣ and EGFR (Garrett et  is with rmsd values of 1.6-2.9 Å for the corresponding C␣ atoms. The primary structure of EGF is divided into the deglycosylated, and crystallized with human EGF (M r of 6.2 kDa). The crystal structure was determined at 3.3 Å A, B, and C loops by the disulfide bonds Cys6-Cys20, Cys14-Cys31, and Cys33-Cys42 ( Figure 3B ). The A loop resolution (Figures 1 and 2) . First, the protein phases were determined by the multiwavelength anomalous (residues 6-19) contains some ␣-helical structure, the B loop (residues 20-31) forms a two-stranded antiparaldispersion (MAD) method, using selenomethioninelabeled EGFR (Figure 2A issue of Cell]). In the case of neuregulin, which is a specific ligand to ErbB-3 and ErbB-4, the N-terminal five Thus, the present complex structure revealed the EGFR residues that interact with the previously identified reresidues were shown to be essential for the binding to ErbB-4 in a study of EGF/neuregulin chimeric proteins ceptor binding residues of EGF.
In each 1:1 complex, domains I, II, and III of EGFR are The first three domains, I (L1), II (S1/CR1), and III (L2), arranged in a C shape, and the EGF is accommodated of EGFR exhibit about 25% sequence identities with the between domains I and III (Figure 1). This is consistent first three domains (L1, Cys-rich, and L2) of the type-1 with the previous biochemical results that domains I and insulin-like growth factor receptor (IGF-1R
TGF group of Gln321, the side chain of Thr324, and the main tated, and their effects on the full-length EGFR activation chain amide group of Thr324, respectively (Garrett et were examined. First, we assayed the EGF-dependent al., 1998).
phosphorylation of the extracellular signal-regulated protein kinases (ERKs) as a probe for the downstream signaling pathway of EGFR expressed in CHO cells (Fig-EGFR Mutagenesis  ure 6A ). In the hydrophobic receptor-dimerization interThe crystal structure of the EGF•EGFR complex reface, Tyr251 of one receptor hydrogen bonds with vealed the dimerization interface between the two receptors. Thus, the interface residues of EGFR were muArg285 and hydrophobically interacts with Phe263 of the other receptor ( Figures 4C and 4D) . The replacement ceptor dimerization interface found in the present crystal structure was verified by the mutagenesis. Intriguingly, of Arg285 by Tyr (R285Y) had a negligible effect, but that by Ser (R285S) reduced the bioactivity (Figure 6A) . the two dimerization-interface mutants exhibited much lower affinities for EGF in the [ 125 I]EGF binding assay Furthermore, the combination of the R285S mutation with either Y251A or F263A caused a nearly complete ( Figure 6D ), suggesting that the high-affinity EGF binding is related to the EGFR dimerization. loss of the activity, while the individual Ala mutations of Tyr251 and Phe263 exhibited negligible effects. The cell On the other hand, the intramolecular interaction between domains II and III of EGFR was also tested by surface expression levels of both EGFR mutants that failed to activate the ERK were confirmed to be nearly the mutagenesis. In this domain•domain interface, Glu293 of domain II and Arg405 of domain III form a salt the same as that of the wild-type EGFR, by both biotinylation ( Figure 6B ) and FACS analyses (data not shown).
bridge with each other ( Figure 5C ). Correspondingly, the replacement of Arg405 by Glu abolished the EGFThese nonsignaling forms were also incapable of EGFR autophosphorylation ( Figure 6C) . Consequently, the redependent ERK phosphorylation, autophosphorylation, sylated EGFR was purified on the Mono-Q column in the same way A forward oligonucleotide primer was used in a standard PCR protoas for the first Mono-Q chromatography, as described above. col with a reverse oligonucleotide primer that encodes a thrombin For the production of selenomethionyl EGFR, DMEM/F12 concleavage site, a FLAG epitope, and a stop codon. The plasmid taining 50 mg/l fresh selenomethionine (substituted for methionine), encoding the full-length human EGFR was used as the template 1% dialyzed calf serum, 100 units/ml penicillin, 100 g/ml strepto- (Sato et al., 2000) . The amplified DNA was cloned into the pcDNA3.1/ mycin, and 40 mg/l proline (SeMet medium) was prepared. Lec8 Zeo(ϩ) vector (Invitrogen) to create the plasmid pcDNA-sEGFR transfectants were grown in the same way as for the production of (amino acid residues 1-619). Lec8 cells (CRL-1737, American Tissue native EGFR, and then the medium was changed to SeMet medium. Culture Collection) were transfected with the plasmid by the LipofecAfter a 12-24 hr preincubation, the cells were incubated in fresh tamine method, according to the manufacturer's recommendations SeMet medium for 3 days, and then the medium was harvested. (GIBCO-BRL). Stable transfectants were obtained as previously deSelenomethionyl EGFR was purified in the same way as for the native EGFR, as described above. scribed (Kim et al., 2002) .
Crystallization

Mutagenesis Studies
The site-directed mutagenesis was performed with the QuickThe EGF•EGFR complex solution for crystallization was prepared as follows. The purified EGFR solution was concentrated to 10 Change site-directed mutagenesis kit, according to the manufacturer's recommendations (Stratagene). The mutation in the EGFR semg/ml, as determined using the extinction coefficient at 280 nm (0.79). An eqimolar amount of recombinant human EGF (Pepro-Tech) quence was confirmed by DNA sequence analysis. CHO cells were maintained in Minimum Essential Medium Alpha, supplemented with was purified by reversed phase HPLC, freeze-dried, and dissolved in the EGFR solution to form the complex. The crystals were grown 10% calf serum, and were transfected with an expression vector carrying the wild-type or mutant receptor by the FuGENE6 method, at 20ЊC by the hanging-drop vapor diffusion method over a period of 3 weeks, starting from 3 l of the complex solution and 3 l of according to the manufacturer's recommendations (Roche). Then, the transiently transfected CHO cells were maintained for 24 hr, reservoir solution containing 15% PEG4000, 1% PEG6000, 75 mM Tris-HCl (pH 8.4), 75 mM sodium acetate, and 200 mM sodium unless otherwise described, and were used for further analyses with and without a 24 hr starvation, followed by stimulation with human chloride. The macroseeding method was used to reproducibly grow the crystal to 1 ϫ 0.2 ϫ 0.2 mm or more.
EGF 24 hr and then were starved for 24 hr in serum-free medium. The cells were incubated with 2 nM 125 I-labeled EGF in phosphate-buffered saline (PBS) containing 1 mg/ml BSA for 1 hr. The free 125 IStructure Determination and Refinement EGF was removed by washing three times with ice-cold PBS conThe data set of the selenomethionine-labeled crystal at the peak taining 1 mg/ml BSA. The cells were lysed in 0.5 ml of 0.5 M NaOH, wavelength was used to locate the selenium atoms, using the proand the radioactivity was measured by a ␥ counter. gram SnB (Weeks and Miller, 1999) . The 13 peaks were picked out of the 20 atoms expected in the asymmetric unit (Figure 2A) . The
